O

OrganOx

Portable, automated organ perfusion for transplantation

Software Engineer - Quality & Process

Full-TimeUpdated on 10/18/2026
No salary listed
Mid
Bachelor's
Oxford, UK
In Person
Biology & BiotechRegulatory & Quality (Life Sciences)

About the job

Requirements
  • Demonstrated experience in a similar role, preferably within the medical device industry.
  • Proven experience in software quality assurance focused on cloud solutions and software for medical devices.
  • Strong understanding of software development, testing methodologies, tools, and processes.
  • Proven experience applying medical-device regulatory standards, including ISO 13485, FDA regulations, EN 62304, and IEC 62366.
  • Engineering experience in software risk management under ISO 14971, including cybersecurity risk management.
  • Knowledge of medical device software lifecycle processes.
  • Familiarity with cybersecurity standards and frameworks, including IEC 62443 and the NIST Cybersecurity Framework.
  • Bachelor’s degree in computer science, engineering, or a related field.
  • Relevant certifications in software quality assurance or testing, such as ISTQB.
Responsibilities
  • Develop, implement, and maintain the Software Technical File for products, define the documentation strategy, and facilitate submissions.
  • Act as the primary interface between Software and Quality and Regulatory teams.
  • Participate in developing and maintaining software processes that meet relevant regulatory requirements, including Standard Operating Procedures and Working Instructions.
  • Define and execute improvement activities, including Corrective Actions Preventive Actions.
  • Oversee Software of Unknown Provenance and tool validations to secure compliance with the internal Quality Management System.
  • Create software-related documentation, including requirements, design, test reports, and traceability, ensuring regulatory compliance and rigorous documentation of derived outcomes.
  • Develop templates for software documentation and facilitate their integration with the software development toolchain, including Continuous Integration/Continuous Deployment artifacts.
  • Manage partnerships proactively and prepare and maintain test plans, test cases, test scripts, and test reports.
  • Drive software risk analysis, including developing and maintaining Failure Mode and Effects Analysis, identifying mitigations, and including them in design input documentation.
  • Drive cybersecurity activities, including threat modeling and penetration tests, and identify, assess, and mitigate software-related and cybersecurity risks, including those associated with outsourced development and testing processes.
  • Develop and maintain a risk management plan in accordance with relevant standards and frameworks, ensuring identified risks are documented and mitigated.
  • Lead regular, comprehensive reviews and updates of software-related risks through the software Failure Mode and Effects Analysis throughout the software development lifecycle.
  • Work closely with software developers, product managers, and other partners to understand requirements and design effective testing strategies.
  • Communicate findings, risks, and recommendations clearly and promptly to technical and non-technical stakeholders.
  • Adhere to and model the spirit of OrganOx’s Code of Conduct and other company policies.
Desired Qualifications
  • Proven experience with cloud platforms such as AWS, Azure, or Google Cloud and Internet of Medical Things solutions.
  • Familiarity with programming languages such as Python, Java, C#, or C/C++.
  • Proven experience with Continuous Integration/Continuous Deployment pipelines.

About the company

OrganOx develops and commercializes organ perfusion technology to keep donor organs viable for transplantation. The flagship metra device perfuses livers with oxygenated blood at body temperature, delivering nutrients and drugs to mimic normal physiology and allow viability assessment for up to 24 hours. Unlike traditional cold storage, it maintains normothermic conditions and offers direct organ assessment and longer preservation; it leases devices to transplant centers and uses disposable sets. Its goal is to increase transplantable livers and expand to other organs and applications.

Company Size

201-500

Company Stage

Acquired

Total Funding

$73.9M

Headquarters

Oxford, United Kingdom

Founded

2008

Get referred to OrganOx

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Metra gained FDA approval for air transport on September 18, 2025, expanding logistics.
  • OrganOx said metra has been used in over 10,000 liver transplants by August 2026.
  • NICE endorsed routine NHS funding, which should accelerate U.K. adoption and reimbursement.

What critics are saying

  • TransMedics competes directly, and NICE excluded its OCS Liver from NHS funding.
  • OrganOx remains transplant-liver focused; failure to extend beyond metra concentrates revenue risk.
  • Post-acquisition integration into Terumo can slow execution and dilute OrganOx's entrepreneurial speed.

What makes OrganOx unique

  • OrganOx metra keeps donor livers metabolically active, enabling viability assessment before transplant.
  • Terumo completed the $1.5 billion acquisition on October 30, 2025, validating the platform.
  • NICE HTG780 named metra for routine NHS funding across England on August 20, 2026.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Dental Insurance
  • Vision Insurance
  • Disability Insurance
  • Health Savings Account/Flexible Spending Account
  • 401(k) Company Match
  • Paid Vacation
  • Paid Holidays
  • Wellness Program
  • Employee Discounts

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

-1%

2 year growth

6%
TXF
Aug 24th, 2026
Terumo gets ECA support for OrganOx acquisition.

Terumo gets ECA support for OrganOx acquisition. Manufacturing & equipment Asia-Pacific, Europe JBIC signed a JPY49 billion ($307.1 million) loan with Terumo to fund part of its acquisition of UK organ preservation device company OrganOx. The financing is being provided in co-financing with private financial institutions, bringing the total co-financing amount to JPY99 billion ($620.4... Exclusive subscriber content... Not yet a subscriber? Join TXF Limited today to continue accessing content without any restrictions Or to request access to TXF Intelligence contact TXF Limited

Medical Device Network
Jan 7th, 2026
Terumo announces US launch of safety syringe

Terumo announces US launch of safety syringe. The SafeR technology equips the SurTract Safety Syringe with a fully passive, automatic retraction mechanism. Terumo Medical has announced the launch of its SurTract Safety Syringe in the US, incorporating Roncadelle Operations' SafeR passive safety technology. The syringe will be distributed to clinics, emergency-care settings and hospitals across the country starting from the first quarter of this year. The SafeR technology equips the SurTract Safety Syringe with a fully passive, automatic retraction mechanism. This feature withdraws the needle into the plunger after use immediately, aiming to reduce needle-stick injury risks for healthcare professionals. The system also maintains standard clinical technique while enhancing safety and ease of use. The SurTract Safety Syringe also offers a needle selection that can be customised specifically for use with SurTract Syringes, enabling physicians to choose combinations best suited to patient needs. In addition, the syringe provides a blunt needle option, which helps prevent dullness and allows for needle replacement during aspiration. US tariffs are shifting - will you react or anticipate? Don't let policy changes catch you off guard. Stay proactive with real-time data and expert analysis. The design contributes to less medical waste by eliminating an external plastic safety sheath. Terumo vice-president Bob Klock said: "The SurTract Syringe combines Terumo's trusted clinical know-how with Roncadelle's validated SafeR technology to deliver a simple, effective solution for safer injections. It gives healthcare providers more - and better - treatment options for their patients, which is our ultimate goal." Roncadelle operations chief business development officer Dr Fred Metzmann said: "Terumo has significantly advanced injection safety with the integration of our SafeR technology. Together, we are delivering a next-generation syringe system that is intuitive, reliable, and engineered to protect healthcare professionals." The company's SafeR product line includes needle-guard systems and passive safety syringes designed for safe injection and protection in clinical environments. In October 2025, Terumo completed its previously announced acquisition of OrganOx for nearly $1.5bn after meeting all necessary regulatory and closing requirements.

MD+DI
Aug 28th, 2025
Medtech in a Minute: A Verily Big Decision & More

Terumo has agreed to acquire OrganOx for about $1.5B. OrganOx specializes in advanced Normothermic Machine Perfusion devices for organ preservation.

UK Tech News
Aug 26th, 2025
Japan's Terumo acquires Oxford health tech in $1.5bn deal

OrganOx, a University of Oxford spinout that has developed an automated device to preserve organs in transit, has been acquired by Tokyo-based medical manufacturer Terumo for $1.5bn (£1.1bn).

TechStartups
Aug 25th, 2025
Oxford spinout OrganOx acquired by Terumo for $1.5 billion, largest university spinout exit in UK history

From lab to $1.5B exit: Oxford spinout OrganOx acquired by Terumo.